Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amgen's Phase 2 MariTide data to be presented at the American Diabetes Association 85th Scientific Sessions

June 17, 2025

Amgen and football legend Barry Sanders highlight dangers of bad Cholesterol in new documentary

June 12, 2025

Amgen to present at goldman sachs 46th annual global healthcare conference

June 4, 2025

IMDELLTRA® significantly reduced risk of death by 40% in small cell lung cancer patients

June 1, 2025

Amgen to present at jefferies global healthcare conference

May 29, 2025

Amgen to present at the 2025 rbc capital markets global healthcare conference

May 15, 2025

Amgen to present at the bank of america merrill lynch global healthcare conference

May 8, 2025

Amgen reports first quarter 2025 financial results

April 30, 2025

Amgen announces webcast of 2025 first quarter financial results

April 27, 2025

Amgen announces $900 million manufacturing expansion, creation of 350 new jobs in Ohio

April 24, 2025

IMDELLTRA® demonstrated superior overall survival in small cell lung cancer

April 10, 2025

UPLIZNA® (inebilizumab-cdon) is now the first and only FDA-approved treatment for IGG4-related disease

April 2, 2025

UPLIZNA® (inebilizumab-cdon) significantly improves generalized myasthenia gravis symptoms in acetylcholine receptor autoantibody-positive patients over 52 weeks

March 12, 2025

Amgen and Kyowa Kirin provide top-line results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis

March 7, 2025

Amgen announces 2025 second quarter dividend

March 3, 2025

Positive results from TEZSPIRE® (tezepelumab-ekko) phase 3 waypoint trial highlight rapid, sustained effect in chronic rhinosinusitis with nasal polyps

February 28, 2025

Amgen to present at the 45th annual td cowen health care conference

February 27, 2025

Amgen to present at citi's 2025 virtual oncology leadership summit

February 13, 2025

Amgen to present at the 35th annual oppenheimer healthcare life sciences conference

February 6, 2025

Amgen reports fourth quarter and full year 2024 financial results

February 3, 2025

Amgen announces webcast of 2024 fourth quarter and full year financial results

January 30, 2025

FDA approves LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer

January 16, 2025

Amgen to present at 43rd annual j.p. morgan healthcare conference

January 7, 2025

Amgen announces 2025 first quarter dividend

December 9, 2024

BLINCYTO® (blinatumomab) added to chemotherapy significantly improves survival in newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia (B-ALL)

December 6, 2024

Amgen announces $1 billion manufacturing expansion in North Carolina

December 4, 2024

Amgen to present at citi's 2024 global healthcare conference

December 1, 2024

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

November 28, 2024

Amgen to host webcast to discuss maritide phase 2 results and progress on development program

November 25, 2024

Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a Phase 2 study

November 25, 2024

Amgen announces senior executive research appointment

November 19, 2024

Amgen presents new data across rare inflammatory diseases at acr 2024

November 13, 2024

Amgen provides statement on MariTide Phase 1 data

November 12, 2024

Amgen to present at the 2024 ubs global healthcare conference

November 7, 2024

TEZSPIRE met both co-primary endpoints in Phase 3 trial for chronic rhinosinusitis with nasal polyps

November 6, 2024

Amgen reports third quarter 2024 financial results

October 29, 2024

Amgen announces 2024 fourth quarter dividend

October 24, 2024

Amgen announces webcast of 2024 third quarter financial results

October 23, 2024

Amgen presents positive Phase 3 data for UPLIZNA® (inebilizumab-cdon) in generalized Myasthenia Gravis (gMG) at aanem 2024

October 14, 2024

La La Anthony partners with Amgen to share candid, behind-the-scenes look at how plaque psoriasis affects her life

September 30, 2024

TEPEZZA® (teprotumumab) receives approval in Japan for the treatment of active thyroid eye disease

September 23, 2024

Amgen to host conference call to discuss new topline data in inflammation and rare disease

September 22, 2024

Amgen to present data from multiple early-stage clinical trials at ESMO 2024

September 12, 2024

Amgen presents new data for first-in-class IMDELLTRA™ (tarlatamab-dlle) in small cell lung cancer at wclc 2024

September 8, 2024

Amgen to present at the 2024 wells fargo healthcare conference

August 29, 2024

Amgen to present at the morgan stanley 22nd annual global healthcare conference

August 28, 2024

Otezla® (apremilast) now available in the U.S. for moderate to severe pediatric plaque psoriasis

August 19, 2024

Amgen reports second quarter 2024 financial results

August 5, 2024

Amgen announces 2024 third quarter dividend

August 1, 2024

Amgen announces webcast of 2024 second quarter financial results

July 31, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.